Oncocyte Publishes Study Demonstrating Predictive Potential
Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient’s response to immunotherapy...
Source: globenewswire.com
Oncocyte Determa News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Oncocyte Determa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Oncocyte Determa Today - Breaking & Trending Today
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
Message : Required fields Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT IRVINE, Calif., April 10, 2021...
Source: marketscreener.com
OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares
Shares of OncoCyte Corp. OCX, -1.98% rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd. BNR, -0.72% to bring OncoCyte's DetermaRX test for early-stage lung cancer patients to China. Trading volume spiked to 8.3 million shares, compared with the full-day average of about 419,500 shares. "This agreement with Burning Rock accelerates the ongoing expansion of our DetermaRx test to patients and phys...
Source: marketwatch.com